In Brief
Cancer patients often suffer from cancer cachexia and paraneoplastic syndrome, which significantly impair survival and the quality of life. Here, Lim et al. report that tumor-derived VEGF induces anemia in mice through the mechanism of vessel dilation in bone marrow. The VEGF-VEGFR2-triggered vascular dilation in bone marrow leads to mobilization of bone marrow cells to peripheral tissues and organs. These findings suggest a therapeutic option for treatment of cancer anemia by targeting VEGF-VEGFR2 signaling.
Molecular mechanisms underlying tumor VEGFinduced host anemia and bone marrow cell (BMC) mobilization remain unknown. Here, we report that tumor VEGF markedly induced sinusoidal vasculature dilation in bone marrow (BM) and BMC mobilization to tumors and peripheral tissues in mouse and human tumor models. Unexpectedly, anti-VEGFR2, but not anti-VEGFR1, treatment completely blocked VEGF-induced anemia and BMC mobilization. Genetic deletion of Vegfr2 in endothelial cells markedly ablated VEGF-stimulated BMC mobilization. Conversely, deletion of the tyrosine kinase domain from Vegfr1 gene (Vegfr1 TKÀ/À ) did not affect VEGFinduced BMC mobilization. Analysis of VEGFR1 + / VEGFR2 + populations in peripheral blood and BM showed no significant ratio difference between VEGF-and control tumor-bearing animals. These findings demonstrate that vascular dilation through the VEGFR2 signaling is the mechanism underlying VEGF-induced BM mobilization and anemia. Thus, our data provide mechanistic insights on VEGFinduced BMC mobilization in tumors and have therapeutic implications by targeting VEGFR2 for cancer therapy.
INTRODUCTION
In the tumor microenvironment, tumor cells together with other host cellular components including inflammatory cells, stromal fibroblasts, and vascular cells collectively contribute to tumor development, progression, invasion, and metastasis (Hanahan and Weinberg, 2011) . Malignant cells and the tumor-infiltrated host cells reciprocally interact with each other. This complex and intimate crosstalk is accomplished through various growth factors, cytokines, and cell-cell interactions. Genetic and epigenetic alterations, as well as microenvironmental changes, often lead to production of various growth factors and cytokines at high levels. Vascular endothelial growth factor (VEGF) is one of the most frequently highly expressed angiogenic factors found in various tumor tissues (Jubb et al., 2004) , and its expression level can be further elevated by tissue hypoxia that often exists in solid tumor (Makino et al., 2001 ). Although VEGF is described as one of the relatively specific endothelial growth factors, it displays broad biological functions by targeting other cell types, including tumor, perivascular, hematopoietic, inflammatory, and neuronal cells (Cao, 2014; Ferrara et al., 2003) . These broad tissue effects are determined by the specific distribution of VEGFRs on particular cell types.
VEGF displays its biological functions by activation of its receptors, and it is generally believed that VEGFR2, a cell-surface tyrosine kinase receptor, is the functional receptor that mediates VEGF-induced angiogenesis, vascular permeability, and vascular remodeling (Ferrara et al., 2003; Senger et al., 1983) . Conversely, biological functions of VEGFR1-mediated signals remain largely unknown, and it has been suggested that VEGFR1 mediates negative signals that counteract VEGFinduced angiogenesis (Cao, 2009) . Based on its relatively broad distribution in various cell types, some of the VEGF-induced nonendothelial activity has been associated with the VEGFR1-signaling system. For example, VEGFR1 is expressed in macrophages and hematopoietic progenitor cells and has been reported to be involved in recruiting these cells to the tumor microenvironment (Cao, 2009) . Once these hematopoietic progenitor and inflammatory cells are recruited to the tumor microenvironment, they significantly contribute to tumor neovascularization. Additionally, VEGF-mobilized bone marrow cells (BMCs) may significantly contribute to cancer metastasis by facilitating malignant cell intravasation and the formation of premetastatic niches in remote organs (Kaplan et al., 2005; Wynn et al., 2013) .
In this study, we use several mouse tumor models to study the underlying mechanism by which tumor-derived VEGFs mobilize BMCs. Surprisingly, we found that the mechanism underlying the VEGF-induced BMC mobilization is mediated via VEGFR2-dependent vascular dilation in bone marrow (BM) but independent from VEGFRs expression in BMCs. Thus, targeting endothelial cell VEGFR2, but not VEGFRs in hematopoietic cells, would be an effective approach to inhibit VEGF-stimulated BMCs, which may significantly participate in tumor growth, angiogenesis, and metastasis.
RESULTS
Tumor-Derived VEGF Induces BMC Mobilization, Vascular Dilation, and Permeability To study the systemic impact of tumor-derived VEGF on BMCs, we established a murine fibrosarcoma (T241) cell line that produces VEGF 165 (Xue et al., 2008; Yang et al., 2013a; Zhang et al., 2011) . Tumor cells were subcutaneously implanted in syngeneic wild-type (WT) C57Bl6 mice, and BM was analyzed when tumor volume reached approximately 1 cm 3 in vector-and VEGF-T241 tumors. The tumor-derived circulating VEGF was detectable in plasma of tumor-bearing mice. The plasma level of VEGF-tumor-bearing mice was significantly higher than that of control tumor-bearing mice (1.2 ng/ml versus 0.06 ng/ml; Figure S1A ). Compared with vector-tumor control mice, VEGFtumor-bearing mice exhibited a severe hematopoietic defect, manifesting robust depletion of BMCs, with an exception of remaining BMCs attached to the bone matrix ( Figure 1A ). Quantification analysis showed a significant reduction of BMCs in VEGF-tumor-bearing mice relative to controls ( Figure 1C ). Vascular immunohistochemical staining with endomucin as a sinusoidal endothelial-cell-specific marker (Wang et al., 2013) demonstrated that BM microvessels underwent marked dilation in VEGF-tumor-bearing animals relative to control groups (Figure 1B) . Owing to dilation of sinusoidal microvessels in BM, vascular density per field was significantly decreased ( Figure 1C) . Notably, BM microvessels were also dilated in vector control tumor-bearing mice, although this effect remains relatively modest ( Figures 1A-1C) . Consistent with BM defects, peripheral red blood cells (RBCs), hemoglobin (HGB), and hematocrit (HCT) in VEGF-tumor-bearing mice were all significantly decreased relative to those of tumor-free healthy mice ( Figure S1B ).
Similar to VEGF 165 , overexpression of VEGF 121 , a non-heparin-binding soluble VEGF isoform, in tumors also markedly induced BM vessel dilation and BMC loss ( Figure S2 ). In contrast, expression of VEGF 189 , a high-affinity heparin-binding VEGF isoform, did not alter BM vasculatures and BMC mobilization ( Figure S2 ). These findings indicate that non-heparinbinding soluble VEGF molecules are responsible for BM vessel dilation and BMC loss. In contrast to VEGF, overexpression of PlGF and VEGF-B in the same tumor type did not induce vessel dilation and BMC loss ( Figure S2 ). Because PlGF and VEGF-B are VEGFR1 exclusive binding ligands, which lack interactions with VEGFR2, these findings provide independent evidence to further support the VEGFR2-dependent mechanism underlying VEGF-induced BMC loss.
To exclude the possibility that BMC loss was the causal mechanism of BM vessel dilation, we employed irradiation as an alternative approach to induce BMC loss. As expected, irradiation effectively induced BMC loss in mice without causing vessel dilation ( Figures 1D and 1E ). These findings suggest that BMC loss per se would not significantly alter BM vessel dilation, and VEGF-induced vessel dilation and BMC loss occurred as a sequential event. The other possible mechanism underlying VEGF-induced BMC mobilization is the increase of vascular permeability of BM vasculatures. To study this possibility, large-size rhodamine-labeled 2,000 kDa dextran molecules were injected into tumor-bearing mice. Notably, BM vasculatures of VEGF-tumor-bearing mice showed high permeability of 2,000 kDa dextran whereas BM vasculatures of vector control tumor-bearing mice were completely nonpermeable to these large-size dextran molecules ( Figures 1F and 1G ). In fact, nearly all injected dextran molecules were extravasated in BM of VEGFtumor-bearing mice. The highly permeable BM vessels are likely to provide another mechanism of BMC mobilization. Consistent with increased mobilization of BMCs, peripheral blood mononuclear cells (PBMCs) were transiently increased, followed by a decrease ( Figure 1H ). The fluctuation of white blood cells (WBCs) reflects the dilation-permeability-related mobilization of BMCs and subsequently BM crisis.
VHL Mutation-Induced VEGF in Human Renal Cell Carcinomas Causes BM Vascular Dilation and Anemia To link our findings to pathophysiological relevance, we studied the impact of tumor-derived VEGF on BM vessels in naturaloccurring human tumors. For this reason, we chose a human renal cell carcinoma (768-O RCC-mutVHL) with VHL mutations, which often leads to high expression of VEGF due to stabilization of hypoxia-inducible factor-1a (HIF-1a). Reconstitution of WTVHL into the 768-O RCC-mutVHL enabled us to use the cell line of the same background to study the role of VHL mutation in modulation of BM vascular dilation and BMC mobilization.
The circulating VEGF level of 768-O RCC-mutVHL-tumorbearing mice was high (approximately 500 pg/ml) as compared with that of 768-O RCC-WTVHL-tumor-bearing mice (Figure 2A) . Consistent with the high-circulating VEGF level, 768-O RCCmutVHL-tumor-bearing mice exhibited suppression of BM hematopoiesis by losing BMCs ( Figure 2B) . Examination of BM microvessels demonstrated that BM vasculatures became highly dilated, as seen in the mouse tumor models ( Figure 2C ). The sinusoidal BM microvessels appeared to be disorganized with large and irregular lumen as compared with those of 768-O RCC-WTVHL-tumor-bearing mice ( Figure 2D ). Consistent with BM morphology, 768-O RCC-mutVHL-tumor-bearing mice suffered from anemia with reduced RBCs, HGB, and HCT values ( Figure 2E ). These findings in human renal cell carcinoma (RCC) tumors demonstrate the pathophysiological relevance of our findings and indicate that VHL mutations potentially contribute to development of tumor-associated anemia through the mechanism of VEGF-induced BM vessel dilation.
VEGFR2-Dependent Vessel Dilation and BMC Mobilization
We next studied the VEGFR-signaling pathway that mediates microvessel dilation and BMC mobilization. Anti-mouse VEGFR1-and VEGFR2-specific neutralizing antibodies (Yang et al., 2013b) were used to block VEGF-triggered functions. Interestingly, VEGFR2-, but not VEGFR1-, specific blockade virtually completely reversed the VEGF-induced BM defect (Figure 3A) . The density of BMCs in VEGFR2 blockade-treated tumor-bearing mice reversed to similar levels of healthy and vector tumor controls ( Figure 3C ). Consistent with BMC recovery, anti-VEGFR2-treated VEGF-tumor-bearing mice showed normalization of BM vessels with substantial reduction of vascular diameters nearly to those seen in control-vector-tumor-bearing (F) Perfusion of lysinated 2,000 kDa dextran (green) in BM microvessels that were costained with endomucin (red) of vector-and VEGF-tumor-bearing mice (n = 6). Arrows indicate perfused area (yellow). Arrowheads point to extravasated dextran signals (green). (G) Quantification of vascular perfusion and extravasated dextran signals (n = 6-8). LRD, lysinated rhodamine dextran. (H) WBCs from peripheral blood of tumor-free and VEGF tumor-bearing mice were measured (n = 4-6). The scale bars of each panel represent 50 mm. All data are represented as mean ± SEM. **p < 0.01; ***p < 0.001 (Student's t test; two-tailed). See also Figure S1 . mice ( Figures 3B and 3E ). Consequently, microvessel density was significantly increased as measured per field of BM sections ( Figure 3D ). Similar to VEGFR2 blockade, treatment of VEGF-tumor-bearing mice with an anti-mouse VEGF neutralizing antibody resulted in recovery of BMCs and vascular normalization ( Figures 3A-3E ). In sharp contrast, treatment with the VEGFR1 blockade did not significantly affect tumor VEGF-induced vessel dilation and BMC mobilization ( Figures  3A-3E ). To provide further supportive evidence of VEGFR2 activation in endothelial cells, we isolated endothelial cells from BM of VEGF-and vector-tumor-bearing mice. Notably, a substantial amount of VEGFR2 molecules became phosphorylated in BM endothelial cells of VEGF-tumor-bearing mice as compared with those in vector-tumor-bearing mice ( Figure 3F ). These findings indicate that VEGFR2-mediated signaling is crucial for tumor VEGF-stimulated BMC mobilization.
VEGFR2 Blockade Inhibits BMC Mobilization to Tumor and Peripheral Tissues
To trace mobilization of BMCs to tumor and peripheral tissues, we next performed bone marrow transplantation experiments using BMCs from enhanced GFP (EGFP) mice. In these experimental settings, C57Bl6 syngeneic recipient mice were irradiated, followed by BM transplantation with EGFP + BMCs from the donor. Xenograft of T241 tumor cells were subcutaneously implanted into recipient mice after 3 weeks of BM transplantation, and tumor-bearing mice were randomly divided into different groups that received various treatments. Consistent with VEGF-induced BMC depletion, tumor-derived circulating VEGF molecules were able to markedly increase mobilization of EGFP + BMCs to tumor and hepatic tissues relative to that of vector-control tumor-bearing mice ( Figures 4A-4C ). The increased EGFP + BMCs to tumor and hepatic tissues were unlikely due to the consequence of increased proliferation of the resident BMCs because these cells were not actively proliferating ( Figures 4D and 4E ). These findings further validate the fact that circulating VEGF significantly mobilized BMCs to peripheral tissues, resulting in a decreased number of resident cells in BM. Interestingly, treatment of tumor-bearing recipient mice with the VEGFR2 blockade markedly prevented VEGF-induced mobilization of BMCs to tumors and liver ( Figures 4A-4C ), supporting the critical role of VEGFR2 in mediating mobilization of BMCs to peripheral tissues. Likewise, a VEGF-specific blockade produced a similar inhibitory effect on BMC mobilization in tumor and liver ( Figures 4A-4C ). Again, VEGFR1 blockade had no effect on mobilization of EGFP + BMCs to tumor and liver. These findings further support the fact that VEGFR2-, but not VEGFR1-, mediated signals are essential for BMC mobilization in our tumor models.
Reversible Recovery of Hematopoiesis and Microvasculature after Tumor Removal
Because VEGFR1 and VEGFR2 are expressed in subsets of hematopoietic cells and WBCs (Kumar et al., 2003; Lyden et al., 2001) , it is possible that pharmacological interference with VEGFR1 and VEGFR2 blockades would affect BMC production under physiological conditions. It is also highly possible that VEGF plays a crucial role in maintenance of BM microvasculatures. Thus, the effects of anti-VEGFR1 and anti-VEGFR2 treatments in our tumor models could be due to their direct impact on BMCs and microvasculatures, which were not influenced by tumors. To exclude these possibilities, we treated tumor-free healthy mice with VEGFR1 and VEGFR2 blockades. Notably, neither VEGFR1 nor VEGFR2 blockades produced any significant effects on the total BMC population, microvessel density, and vascular dilations ( Figure S3A ). To study if tumor-derived VEGF-induced BMC depletion and vascular dilation were reversible, we next performed experiments by removing primary tumors in mice that had already developed severe BM phenotypes. Expectedly, BMCs and BM microvessels were almost completely recovered after only 2-week tumor removal ( Figure S3B) . These findings further demonstrate that tumor-derived VEGF is primarily responsible for causing the BM phenotype. To further study if tumorremoval-recovered BMCs and microvasculatures were dependent on VEGF, three groups of mice, upon resection of primary tumors, were treated with VEGFR1, VEGFR2, and VEGF blockades, respectively. Interestingly, all three anti-VEGF agents had no effects on BMC and microvasculature recovery after removing primary tumors ( Figure S3C ).
Genetic Inactivation of VEGFR1 Does Not Affect VEGF-Induced BMC Mobilization
In addition to pharmacological interference, we next studied the role of VEGF-induced BMC mobilization and vascular dilation in Vegfr1 TKÀ/À mice that only carry the tyrosine-kinase-deleted Vegfr1 gene (Hiratsuka et al., 1998; Yang et al., 2013a) . Stimulation of WT cells including endothelial (Figures 5B-5F ). In fact, the VEGF-induced BM phenotypes were virtually indistinguishable in Vegfr1 TKÀ/À mice as compared with those of WT mice ( Figures 1A-1C) . Similarly, values in peripheral blood including RBCs, HCT, HGB, and WBCs in tumor-bearing and non-tumor-bearing Vegfr1 TKÀ/À mice were virtually identical to those seen in WT mice ( Figure S1C ). These findings further Figure S5 .
Endothelial Deletion of Vegfr2
Abrogates VEGF-Induced BMC Mobilization Knowing that VEGFR2 was the crucial receptor for VEGF-induced BMC mobilization, we investigated the in-depth mechanism that underlies VEGF-induced BMC mobilization. A tamoxifen-inducible Tie2 CreERT mouse strain was crossed with Vegfr2 lox/lox (Sato et al., 2011) 
to generate conditional Vegfr2 lox/lox Tie2
CreERT -deficient mice in endothelial cells. We first performed localization studies to detect VEGFR2 and Tie2 expression in BM. Notably, VEGFR2 expression was restricted to endothelial cells as costained with the endothelial cell marker endomucin ( Figure 6A ). However, the Tie2 + signals were less specific for BM vasculatures, and nonendothelial-cell-positive signals were also detected (Figure 6B) CreERT -deficient mice, resulting in a normalized hematopoietic phenotype ( Figures  6D-6F ). In addition, microvessel density was also markedly increased in VEGF tumor bearing in Vegfr2 lox/lox Tie2
CreERT -deficient mice ( Figure 6F ). These findings provide compelling evidence that VEGF-induced BM microvessel dilation through the VEGFR2 signaling in endothelial cells is responsible for VEGFinduced BMC mobilization.
Mobilization of VEGFR1-and VEGFR2-Independent BMCs
To study if circulating VEGF preferentially mobilized subpopulations of VEGFR1 + or VEGFR2 + cells, we performed fluorescence-activated cell sorting (FACS) analysis in BM and peripheral blood. To ensure that specific anti-VEGFR1 and anti-VEGFR2 antibodies against mouse were working in our experimental settings, CD31 + endothelial cell fractions from tumor tissues were used as positive controls. As expected, CD31 + endothelial cell fractions showed positive signals in both anti-VEGFR1 and anti-VEGFR2 analyses ( Figure S4A ). In contrast, a human ovarian cell line completely lacked detectable signals in our FACS analysis ( Figure S4A ). These findings demonstrate that our anti-VEGFR1-and anti-VEGFR2-based FACS analyses are workable in our experimental settings. were not altered in BM of vector-and VEGF-tumor-bearing mice ( Figures S4E-S4G) . Again, the total VEGFR1 + and VEGFR2 + BMCs represent only a tiny population (<0.4%) of total
BMCs. There were no significant ratio changes in tumor-free, healthy, vector-tumor and VEGF-tumor mice. Similarly, the populations of putative Lin(À)/c-Kit(+)/Sca-1(+) hematopoietic stem cells and CD45 + myeloid cells in BM remained unchanged in tumor-free, healthy, vector-tumor and VEGF-tumor mice (Figure S5 ). These findings suggest that preferential mobilization of VEGFR + BMCs is unlikely a mechanism of VEGF-induced BMC depletion and peripheral mobilization.
DISCUSSION
We have recently discovered that tumor-derived circulating VEGF represses bone marrow hematopoiesis by mobilizing BMCs (Figure 7 ; Xue et al., 2008; Zhang et al., 2011) . Consistently, others have also reported that VEGF mobilizes BMCs under various pathological conditions through a possible mechanism of interacting with VEGFRs expressed in BMCs (Shaked et al., 2006) . Unlike the restricted expression of VEGFR2 in a limited number of cells, VEGFR1 exhibits relatively broad expression patterns on a variety of cell types including monocytes/macrophages and granulocytes (Cao, 2009 ). Based on expression of VEGFR1 on certain types of BMCs and infiltration of these cells in tumor tissues, it has been suggested that VEGF is able to mobilize these cells from BM to tumor tissues. Despite this reasonable hypothesis, experimental evidence has been lacking to support selective mobilization of VEGFR1 + BMCs by tumor-derived VEGF. In addition to VEGF, several other factors including angiopoietin1, stroma-derived factor, and granulocyte-colony-stimulating factor have been reported to induce BMC mobilization (Ryan et al., 2010; Youn et al., 2011) . Our present study provides several lines of evidence to exclude a direct role of VEGF in mobilization of specific VEGFR + BMC populations. These include (1) stochastic depletion of BMCs by circulating VEGF that resulted in only scattered hematopoietic islets being attached to the bone matrix; (2) VEGF-induced BMCs depletion occurred in large areas of BM but unlikely vaporized only a particular cell population; (3) despite its broad distribution in BMCs, pharmacological and genetic inactivation of VEGFR1 produced no impact on BMC mobilization; (4) cell population analysis demonstrated that the ratio of VEGF-mobilized VEGFR + and VEGFR À cells in peripheral blood and tissues remained the same as controls, indicating that mobilization occurred indistinctly on all BMCs; (5) inactivation of VEGFR2, which is expressed in a tiny population of BMCs, could virtually completely block tumor VEGFinduced BMC mobilization; and (6) overexpression of VEGFR1 exclusive binding ligands including PlGF and VEGF-B in tumors did not induce vessel dilation and BMC loss. The compelling evidence provided from these data suggests the existence of alternative mechanisms. Examination of blood vessels, the main VEGFR2 + structural component in BM, showed that BM sinusoidal microvessels became high dilated, and the majority of BM area was replaced by vascular lumen. Tumor-derived circulating VEGF-induced vascular dilation also exists in several other tissues and organs including liver, adrenal gland, thyroid, and pancreas (Cao et al., 2004; Eriksson et al., 2003; Feng et al., 1999; Roberts and Palade, 1995; Yang et al., 2013b) . Blood vasculatures in these organs are particularly sensitive to VEGF stimulation, and VEGF is crucial for maintenance of microvessel density (Kamba et al., 2006; Yang et al., 2013b) . Hematopoietic organs including BM, liver, and spleen contain sinusoidal capillaries (Kopp et al., 2009 ) that possess fenestrated endothelium and incomplete basement membrane, which permit RBCs, WBCs, as well protein molecules to pass through. Further dilation of the sinusoidal capillaries in BM by VEGF would facilitate intravasation of BMCs into the circulation. In fact, VEGFinduced dilation of sinusoidal BM vessels is highly permeable to large-molecular-weight dextran. Thus, at least two mechanisms are potentially involved in circulating VEGF-induced BMC depletion: (1) dilation of sinusoidal microvessels and increase of vascular permeability in BM and (2) diminishing hematopoietic niches in BM. Using both pharmacological and genetic approaches, we have found that tumor-derived VEGF-induced BMC mobilization can be completely blocked by inactivation of VEGFR2, but not VEGFR1. These findings are surprising because VEGFR2 is not prominently expressed in BMCs and our localization study shows VEGFR2 expression is restricted in endothelial cells in BM. Notably, genetic deletion of VEGFR2 in endothelial cells largely impaired circulating VEGF-induced mobilization, indicating that the endothelial VEGFR2 mediates BMC mobilization. Although Tie2 expression is not restricted in endothelial cells, specific expression of VEGFR2 in BM endothelial cells would restrict the Tie2
CreERT recombinase activity to endothelial cells.
Thus, the Vegfr2 lox/lox Tie2
CreERT system in our experimental model system is rather restricted to endothelial cells in BM. To the best of our knowledge, this unexpected mechanism has not been described for VEGF-induced mobilization of BMCs. Thus, our findings provide mechanistic insights on how BMCs are mobilized by VEGF under many pathological conditions. In addition to VEGF and VEGFR2 inhibitors, it is likely other angiogenesis inhibitors such as NADPH oxidase inhibitors (Bartus et al., 2011; Bhandarkar et al., 2009; Garufi et al., 2014; Munson et al., 2012) could also alleviate VEGF-induced anemia. Despite our evidence-based claims, we cannot exclude other possible mechanisms of VEGF-related BMC mobilization. For example, VEGF has been shown to play an important role in mobilization of circulating endothelial precursor cells without significantly affecting BM vasculatures (Lyden et al., 2001) . In MMP9-deficient mice, mobilization of VEGF is impaired, leading to defective mobilization of CD45 + myeloid cells (Du et al., 2008) . It is likely that VEGFR1 plays a role in that experimental system. Thus, VEGF-induced BMC cell mobilization may involve complex mechanisms by which different BM cell populations are mobilized by distinct pathways.
Cancer patients, especially those with advanced disease, often suffer from systemic diseases including cancer cachexia and paraneoplastic syndrome. Anemia is one of the most common systemic disorders seen in patients with various types of cancers. Our present findings in mouse tumor models demonstrated that tumor-derived circulating VEGF significantly contributes to tumor-associated hematopoiesis suppression in BM. In fact, these findings are pathophysiologically and clinically relevant. It is known that human tumors often express VEGF at high levels as compared with their healthy tissue counterparts (Jubb et al., 2004) . In particular, a subset of human RCC tumor tissues expresses VEGF to an extremely high level due to carrying mutations in the VHL gene (Jubb et al., 2004) . Functional impairment of VHL leads to stabilization of HIF-1a that transcriptionally upregulates VEGF expression (Maxwell et al., 1999) . It is known that a substantial number of human RCC patients suffer from paraneoplastic anemia, exhibiting sinusoidal dilation of vasculatures in multiple tissues and organs (Cao, 2010) . For example, an early randomized autopsy study of 45 RCC patients showed that 20% of RCC patients exhibited sinusoidal dilation of liver microvessels (Aoyagi et al., 1989) . It is likely that their BM microvessels might also become dilated. In our present study, we show that human tumor cells carrying VHL mutations express high levels of VEGF, which causes sinusoidal dilation of BM microvessels. Interestingly, replacement of the mutated VHL with the WTVHL in the same RCC cells completely abrogates VEGF-induced vascular phenotypes in BM, indicating that functionally defective VHL mutations are responsible for high-VEGF expression and vascular phenotypes in other nonmalignant tissues. This finding also implies that functionally defective VHL mutations could potentially predict BM anemia in RCC patients and even anti-VEGF drug responses. In fact, RCC patients remain one of the particular cancer populations that benefit the most from anti-VEGF therapy (Brugarolas, 2007) . Thus, our findings are clinically relevant.
VEGF-induced sinusoidal dilation is the mechanism for BM hematopoiesis suppression, and therapeutic interference of the systemic effect would be beneficial for host survival. Given the known fact that tumor tissues contain high numbers of inflammatory cells and other hematopoietic cells that collectively contribute to an invasive phenotype and antiangiogenic drug resistance, our present findings imply that blocking the systemic effect of tumor-derived VEGF would be an important approach for antiangiogenic cancer therapy. In support of this view, in preclinical tumor models, survival improvement has been associated with off-tumor targets of anti-VEGF drugs. Our findings also indicate that normal structures and architectures of BM microvessels are crucial for sustaining physiological hematopoiesis, and interference of BM capillary structures would lead to severe functional impairment. Taken together, our data uncover yet another complex mechanism by which tumor-derived VEGF manipulates the host tissues for the benefit of tumor growth, invasion, and escaping drug resistance. (Yang et al., 2013a (Yang et al., , 2013b ). An anti-mouse VEGFR1-neutralizing antibody and a rat anti-mouse VEGFR2-neutralizing antibody were obtained from Dr. Zhenping Zhu at ImClone. A rat anti-mouse endomucin antibody was purchased from eBioscience (cat. no. 14-5851-85).
EXPERIMENTAL PROCEDURES

Mouse Tumor Models
Approximately 1 3 10 6 T241 tumor cells in 100 ml PBS were subcutaneously inoculated on the dorsal back of C57Bl6, Vegfr1 , and treatment lasted for 2 weeks.
Bone Marrow Transplantation
Femur and tibia bones were dissected from the donor EGFP mice immediately after cervical dislocation. BMCs were flushed out with RPMI medium using 21-gauge needles and filtered through a 70 mm nylon mesh cell strainer. BMCs were collected in a 50 ml falcon tube, centrifuged at 1,500 rpm for 6 min, and resuspended in cold PBS. Recipient mice were irradiated at 900 rad gamma rays. Approximately 1.5 3 10 6 donor BMCs were injected into the lateral tail vein of each recipient mouse.
Immunohistochemistry
Fresh bone samples were fixed in 4% paraformaldehyde at 4 C overnight and washed with PBS before paraffin embedding. The embedded samples were cut (5 mm in thickness) and baked at 60 C overnight. Antigen retrieval was achieved using an unmasking solution (Vector Labs; H3300). Samples were blocked with a blocking buffer (4% goat serum in PBS) at room temperature (RT) for 30 min. A rat anti-mouse endomucin antibody (eBioscience; 1:200 dilution in blocking buffer) was used for incubation at 4 C overnight. A secondary fluorescent-conjugated antibody (goat anti-rat Alexa Fluor 555; Invitrogen; A21434; 1:400 dilution in blocking buffer) was incubated at RT for 1 hr. A rabbit anti-mouse VEGFR2 (T104) antibody (1:100 dilution in blocking buffer) or a rat anti-mouse Tie2 antibody (eBioscience E04662; 1:100 dilution in blocking buffer) were used for incubation at 4 C overnight. Secondary fluorescent-conjugated antibodies (goat anti-rat Alexa Fluor 555; Invitrogen; A21434; 1:400 dilution in blocking buffer) and goat anti-rabbit (Alexa 488; Invitrogen; 1:400 dilution in blocking buffer) were incubated at RT for 1 hr. Slides were mounted with Vectashield (Vector Labs; H-1200). Paraffin-embedded samples were sectioned at a thickness of 5 mm and stained with hematoxylin-eosin as described (Hosaka et al., 2013; Lim et al., 2012; Xue et al., 2010 Xue et al., , 2012 .
Immunoblotting Equal amounts of cell lysates were subjected to western blot analysis to detect phosphorylated VEGFR2 by incubation with antibodies against phospho-VEGFR2 (2471; Cell Signaling Technology) was followed by secondary antibody incubation. For analysis of VEGFR1 activation, BMCs were collected from WT and Vegfr1 TKÀ/À and stimulated with recombinant VEGF for 15 min prior to lysis. Total lysates were incubated with an anti-VEGFR1 antibody (ImClone) followed by protein A/G Agarose (Santa Cruz Biotechnology; sc-2003) immunoprecipitation. Samples were subjected to western blot analysis with antibodies against total phosphotyrosine (4G10; 05-1050; Millipore) followed by secondary antibodies. b-actin (3700S; Cell Signaling Technology) was used as loading control for all blots. Positive signals were visualized using an Odyssey CLx system (LI-COR).
ELISA
Mouse and human VEGF were detected using commercially available VEGF ELISA kits (R&D Systems). All procedures were performed according to the manufacturer's instructions.
Statistical Analysis
For quantification analysis, data were analyzed using two-tailed Student's t test. *p < 0.05; **p < 0.01; ***p < 0.001. 
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